A maggot does one job better than most surgeons would care to admit. It eats dead tissue and leaves the living alone. That precision is why the larvae have crawled back into modern clinics after decades on the medical fringe. And now there's a second species cleared for the work.
The U.S. Food and Drug Administration has signed off on another carcass-eating fly for use in maggot wound therapy. It's a tiny corner of medicine, one that has quietly persisted since field hospitals first noticed that infested wounds sometimes healed faster than clean ones. One species was already approved. Now there are two.
It sounds grotesque. It mostly isn't. The treatment is one of the older tricks in wound care, and its return owes more to stubborn bacteria than to nostalgia.
What the larvae actually do
The medical term is debridement: the removal of dead, infected, or otherwise useless tissue so that healthy tissue underneath can rebuild. Surgeons do it with scalpels. Nurses do it with gels and dressings. Larvae do it by feeding.
The maggots used in therapy are raised under sterile conditions, not scooped off roadkill (worth saying out loud, because that's where everyone's mind goes). They're applied to a wound, sometimes loose and sometimes tucked into a mesh pouch, and left to work for a day or two. They dissolve necrotic tissue with their secretions, swallow the slurry, and ignore the parts of the body that are still alive and worth saving.
That selectivity is the whole pitch. A scalpel can't always tell the difference between dead tissue and the fragile new growth right beside it. A hungry larva, evolved over millions of years to strip a carcass efficiently, apparently can.
There's a second benefit too. The secretions seem to discourage bacteria, including some of the drug-resistant strains that make chronic wounds so miserable to treat. For a patient with a diabetic foot ulcer that won't close, or a pressure sore that keeps reopening, that combination matters.
Why a second species is more than a footnote
Approving one more fly might sound like bureaucratic housekeeping. It isn't, quite.
Maggot therapy in the United States has leaned on a single approved species for years. That means a single supply chain, a single set of rearing conditions, and a single point of failure. Live medical products are fussy in ways pills are not. You can't stockpile larvae in a warehouse for three years. They have to be bred, kept alive, shipped fast, and used while fresh.
Add a second cleared species and you add resilience. Different flies tolerate different climates, breed on different timelines, and may suit different kinds of wounds. If one supplier hits a snag, the other isn't necessarily affected. For a niche therapy that depends on a fragile living product, redundancy is the unglamorous thing that keeps it available.
I'd argue that's the real headline. Not the ick factor, which the press will inevitably play up, but the fact that regulators bothered to widen a treatment most people assume belongs to the 1800s. That decision says someone in the system thinks this approach is worth keeping alive. Literally.
A treatment that nearly died out
Maggot debridement has a long, lurching history. Military physicians going back centuries noted that wounded soldiers whose injuries got fly-blown in the field sometimes fared better than expected. The observation hardened into deliberate practice in the early twentieth century, when doctors began applying larvae on purpose to wounds that wouldn't heal.
Then antibiotics arrived. Penicillin and the drugs that followed made the whole idea look quaint, even barbaric. Why grow flies when a pill could clear an infection? Maggot therapy faded almost completely from American medicine for the middle of the century.
It came back for a depressing reason: the pills stopped working as well.
Antibiotic resistance turned some routine infections into stubborn, grinding battles. Chronic wounds, the kind that linger for months in patients with diabetes or poor circulation, became a serious clinical and financial problem. Hospitals needed tools that didn't rely on drugs the bacteria had already learned to shrug off. So in the early 2000s the FDA reclassified medical maggots, putting them back on the official menu as a regulated medical device rather than a folk remedy.
That reclassification is the legal scaffolding everything else hangs on. By treating the larvae as a device, the agency created a path for approval, oversight, and, now, the addition of a second species. It's a strange category (a living animal regulated like a piece of equipment), but it works on paper and in clinics.
The therapy still occupies a small slice of wound care. It's not a first choice for most injuries, and plenty of patients understandably balk when a doctor proposes parking insects on an open sore. Yet for the wounds that resist everything else, it has earned a quiet place on the shelf. Clinicians who use it tend to be evangelists. They've watched it close ulcers that months of conventional treatment couldn't budge, and that kind of result tends to override squeamishness, both the patient's and the provider's.
There's also a cost argument that rarely makes the headlines. Surgical debridement means an operating room, anesthesia, and recovery. A course of larvae is, by comparison, cheap and low-tech. For a health system trying to manage the rising burden of chronic wounds, the math is not nothing. A treatment that's both effective and inexpensive is rare enough that it deserves more attention than the gross-out coverage usually gives it.
The squeamishness problem
None of this erases the obvious hurdle. People do not want maggots near them, full stop.
And that reflex is doing real work against a treatment that, by most clinical accounts, performs well. Patients refuse it. Some doctors don't offer it, either because they've never been trained in it or because they assume the conversation will go badly. The therapy's biggest obstacle may not be science or regulation at all. It might just be the human imagination.
A second approved species won't change that overnight. What it might do is signal, slowly, that this is real medicine with real oversight rather than a horror-movie throwback. Approval lends legitimacy. Legitimacy, over time, chips at stigma.
Whether that's enough to move a squeamish public is an open question. I'm not convinced a regulatory nod alone shifts how someone feels when they picture larvae under a dressing. That's a harder thing to legislate.
What to watch next
The immediate question is practical: which wounds, and which patients, the newly cleared species gets used on. Approval opens the door. Adoption depends on whether wound-care specialists fold the new option into their routines, and whether the supply actually reaches the clinics that want it.
Keep an eye on the chronic-wound numbers too. Diabetic ulcers and pressure sores aren't going anywhere as populations age and diabetes rates climb. Demand for treatments that sidestep failing antibiotics is likely to grow, not shrink. A therapy that was nearly extinct fifty years ago could end up looking, awkwardly, like a tool ahead of its time.
And watch the regulators. Two approved species suggest the FDA isn't treating maggot therapy as a curiosity to tolerate but as a category worth maintaining. If a third application surfaces down the line, that would tell us this small, strange, surprisingly effective field has a future, not just a past.
For now, the wounds that wouldn't close have one more option. Not a pretty one. But the larvae were never selling pretty. They were selling results, and a second species means a few more patients might get the chance to find out whether the old method still earns its keep.